Ascom makes clinical communication hardware and software for hospitals, including DECT handsets, nurse call systems and alarm management platforms that route alerts from patient monitors to care staff. Its moat is installed base: once a hospital has standardised on Ascom handsets and integrated them with its Digistat and nurse call software, switching costs are high and recurring service and software revenue tends to follow the hardware. Revenue growth is flat at -0.1%, so the case rests on margin repair, with operating margin at 5.1% against a 47.8% gross margin, which points to a cost base that has not yet caught up with the revenue line. At 11.2x trailing earnings and 12.5x forward, the stock is priced for little improvement, while a 25.7% return on equity says the capital already in the business is earning well. The company is small at 192M CHF and carries no index membership, so it is the kind of name where a deeper look at the cost base and order book is worth the time.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:53 CEST | ACCE price target | CHF 6.30 | first publication | CHF 5.84 |
| 22 Oct 2026, 14:04 CEST | Rating | Undervalued | first publication | CHF 5.87 |
| 22 Oct 2026, 14:04 CEST | Fair value | CHF 7.12 | first publication | CHF 5.87 |
Answered from Ascom Holding AG fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| ASCN.SW Ascom Holding AG | CHF 5.72 | CHF 7 | 20% below | 11.0x | 25.7% | 78 | 73 |
| SPOK Spok Holdings Inc. Common Stock | $10.30 | $12 | 17% below | 18.8x | 8.4% | 75 | 48 |
| AMWL American Well Corporation Class A Common Stock | $13.57 | - | - | - | -29.1% | 43 | 42 |
| SY So-Young International Inc. American Depository Shares | $2.11 | - | - | - | -15.0% | 43 | 48 |
| CARA.ST Carasent AB (publ) | kr 27.00 | kr 15 | 84% above | 45.8x | 4.8% | 66 | 58 |
| SUS.ST Surgical Science Sweden AB (publ) | kr 57.20 | kr 56 | 2% above | 31.4x | 2.1% | 70 | 63 |
| OPRX OptimizeRx Corporation Common Stock | $9.15 | $9 | 3% below | 38.1x | 3.7% | 54 | 51 |
Where ASCN.SW ranks against its sector peers on each metric.